Approach to the treatment of cutaneous malignancy in HIV-infected patients

Dermatologic Therapy

Volumn 18, Issue 1, 2005, Pages 77-86

  Wilkins, Karl ^a,c   Dolev, Jacqueline C ^a   Turner, Ryan ^b   LeBoit, Philip E ^a   Berger, Timothy G ^a   Maurer, Toby A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c SAN FRANCISCO GENERAL HOSPITAL   (United States)

Author keywords

Basal cell carcinoma; Kaposi's sarcoma and HIV AIDS; Malignant melanoma; Mycosis fungoides; Squamous cell carcinoma

Indexed keywords

ABACAVIR; ALPHA INTERFERON; ALPHA2A INTERFERON; AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIRETROVIRUS AGENT; ATAZANAVIR; BEXAROTENE; BLEOMYCIN; CHORIONIC GONADOTROPIN; DAUNORUBICIN; DELAVIRDINE; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; EMTRICITABINE; ENFUVIRTIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INDINAVIR; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; NUCLEOTIDE; PACLITAXEL; RETINOID; RITONAVIR; SAQUINAVIR; STAVUDINE; SUNSCREEN; TENOFOVIR; THALIDOMIDE; VINCA ALKALOID; ZALCITABINE; ZIDOVUDINE;

BASAL CELL CARCINOMA; ELECTRON BEAM; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; LYMPHOMA; MELANOMA; MYCOSIS FUNGOIDES; PHOTODYNAMIC THERAPY; REVIEW; RISK FACTOR; SKIN BIOPSY; SKIN CANCER; SQUAMOUS CELL CARCINOMA;

CARCINOMA, BASAL CELL; CARCINOMA, SQUAMOUS CELL; HIV INFECTIONS; HUMANS; LYMPHOMA; MELANOMA; SARCOMA, KAPOSI; SKIN NEOPLASMS;

EID: 18844371148     PISSN: 13960296     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1529-8019.2005.05003.x     Document Type: Review

References (148)

1. Palella FJ Jr, Delaney KM, Moorman AC et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study. Invest N Engl J Med 1998: 338: 853-860.
2. Mocroft A, Vella S, Benfield TL et al. Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group. Lancet 1998: 352: 1725-1730.
3. Porter K, Babiker A, Bhaskaran K, Darbyshire J, Pezzotti P, Walker AS. Determinants of survival following HIV-1 seroconversion after the introduction of HAART. Lancet 2003: 362: 1267-1274.
4. Franceschi S, Dal Maso L, Arniani S et al. Risk of cancer other than Kaposi's sarcoma and non-Hodgkin's lymphoma in persons with AIDS in Italy. Cancer and AIDS Registry Linkage Study. Br J Cancer 1998: 78: 966-970.
5. Giordano GG, Sigalotti L, Maio M. New dimensions in cancer biology and therapy. J Cell Physiol 2000: 183: 284-287.
6. Smith C, Lilly S, Mann KP et al. AIDS-related malignancies. Ann Med 1998: 30: 323-344.
7. International Collaboration on HIV and Cancer. Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. J Natl Cancer Inst 2000: 92: 1823-1830.
8. Piketty C, Darragh TM, Heard I et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis 2004: 31: 96-99.
9. + lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000: 95: 3653-3661.
10. Beljaards RC, Kaudewitz P, Berti E et al. Primary cutaneous CD30-positive large cell lymphoma: definition of a new type of cutaneous lymphoma with a favorable prognosis. A European multicenter study of 47 patients. Cancer 1993: 71: 2097-2104.
11. Beylot-Barry M, Vergier B, Masquelier B et al. The spectrum of cutaneous lymphomas in HIV infection: a study of 21 cases. Am J Surg Pathol 1999: 23: 1208-1216.
12. Chadburn A, Cesarman E, Jagirdar J, Subar M, Mir RN, Knowles DM. CD30 (Ki-1)-positive anaplastic large cell lymphomas in individuals infected with the human immunodeficiency virus. Cancer 1993: 72: 3078-3090.
13. Kerschmann RL, Berger TG, Weiss LM et al. Cutaneous presentations of lymphoma in human immunodeficiency virus disease. Predominance of T cell lineage. Arch Dermatol 1995: 131: 1281-1288.
14. Maurer TA, Zackheim HS, Tuffanelli L, Berger TG. The use of methotrexate for treatment of psoriasis in patients with HIV infection. J Am Acad Dermatol 1994: 31: 372-375.
15. Neau D, Trimoulet P, Winnock M et al. Comparison of two regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients. Clin Infect Dis 2003: 36: 1564-1571.
16. Hatzakis A, Gargalianos P, Kiosses V et al. Low-dose IFN-alpha monotherapy in treatment-naïve individuals with HIV-1 infection: evidence of potent suppression of viral replication. J Interferon Cytokine Res 2001: 21: 861-869.
17. + T cells. N Engl J Med 1996: 335: 61-62.
18. Friedler S, Parisi MT, Waldo E, Wieczorek R, Sidhu G, Rico MJ. Atypical cutaneous lymphoproliferative disorder in patients with HIV infection. Int J Dermatol 1999: 38: 111-118.
19. Janier M, Katlama C, Flageul B et al. The pseudo-Sézary syndrome with CD8 phenotype in a patient with acquired immunodeficiency syndrome (AIDS). Ann Intern Med 1989: 110: 738-740.
20. Picard-Dahan C, Le Guyadec T, Grossin M et al. Pigmented erythroderma in AIDS: five cases. Ann Dermatol Venereol 1996: 123: 307-313.
21. Zhang P, Chiriboga L, Jacobson M et al. Mycosis fungoides-like T cell cutaneous lymphoid infiltrates in patients with HIV infection. Am J Dermatopathol 1995: 17: 29-35.
22. Zucker-Franklin D, Pancake BA, Friedman-Kien AE. Cutaneous disease resembling mycosis fungoides in HIV-infected patients whose skin and blood cells also harbor proviral HTLV type I. AIDS Res Hum Retroviruses 1994: 10: 1173-1177.
23. Guitart J, Variakojis D, Kuzel T, Rosen S. Cutaneous CD8 T cell infiltrates in advanced HIV infection. J Am Acad Dermatol 1999: 41: 722-727.
24. Guitart J. HIV-1 and an HTLV-II-associated cutaneous T cell lymphoma. N Engl J Med 2000: 343: 303-304.
25. Cooley TP. Non-AIDS-defining cancer in HIV-infected people. Hematol Oncol Clin North Am 2003: 17: 889-899.
26. Rasokat H, Steigleder GK, Bendick C, Muller S, Meller M. Malignant melanoma and HIV infection. Z Hautkr 1989: 64: 581-582, 587.
27. Frisch M, Biggar RJ, Engels EA, Goedert JJ. Association of cancer with AIDS-related immunosuppression in adults. JAMA 2001: 285: 1736-1745.
28. Calista D. Five cases of melanoma in HIV-positive patients. Eur J Dermatol 2001: 11: 446-449.
29. Solomon RK, Lundeen SJ, Hamlar DD, Pambuccian SE. Fine-needle aspiration diagnosis of unusual cutaneous neoplasms of the scalp in HIV-infected patients: a report of two cases and review of the literature. Diagn Cytopathol 2001: 24: 186-192.
30. McGregor JM, Newell M, Ross J, Kirkham N, McGibbon DH, Darley C. Cutaneous malignant melanoma and human immunodeficiency virus (HIV) infection: a report of three cases. Br J Dermatol 1992: 126: 516-519.
31. Massi D, Borgognoni L, Reali UM, Franchi A. Malignant melanoma associated with human immunodeficiency virus infection: a case report and review of the literature. Melanoma Res 1998: 8: 187-192.
32. Gattuso P, Kluskens L, Reddy V et al. Fine needle aspiration of solid tumors in HIV-positive patients. Acta Cytol 1999: 43: 510-512.
33. Kind GM, VonRoenn J, Jansen DA, Bailey MH, Lewis VL Jr. Human immunodeficiency virus infection and subsequent melanoma. Ann Plast Surg 1996: 37: 273-277.
34. Krause W, Mittag H, Gieler U, Thomas E, Wichmann U. A case of malignant melanoma in AIDS-related complex. Arch Dermatol 1987: 123: 867-868.
35. Rivers JK, Kopf AW, Postel AH. Malignant melanoma in a man seropositive for the human immunodeficiency virus. J Am Acad Dermatol 1989: 20: 1127-1128.
36. Aboulafia DM. Malignant melanoma in an HIV-infected man: a case report and literature review. Cancer Invest 1998: 16: 217-224.
37. van Ginkel CJ, Sang RT, Blaauwgeers JL, Schattenkerk JK, Mooi WJ, Hulsebosch HJ. Multiple primary malignant melanomas in an HIV-positive man. J Am Acad Dermatol 1991: 24: 284-285.
38. Pereira F, Carey W, Shibata H, Burnier MN Jr, Wang B. Multiple nevoid malignant melanomas in a patient with AIDS: the role of proliferating cell nuclear antigen in the diagnosis. J Am Acad Dermatol 2002: 47: S172-S174.
39. Smith KJ, Skelton HG, Yeager J, Angritt P, Wagner KF. Cutaneous neoplasms in a military population of HIV-1-positive patients. Military Medical Consortium for the Advancement of Retroviral Research. J Am Acad Dermatol 1993: 29: 400-406.
40. Tindall B, Finlayson R, Mutimer K, Billson FA, Munro W, Cooper DA. Malignant melanoma associated with human immunodeficiency virus infection in three homosexual men. J Am Acad Dermatol 1989: 20: 587-591.
41. Rodrigues LK, Klencke BJ, Vin-Christian K, et al. Altered clinical course of malignant melanoma in HIV-positive patients. Arch Dermatol 2002: 138: 765-770.
42. Tsao H, Atkins MB, Sober AJ. Management of cutaneous melanoma. N Engl J Med 2004: 351: 998-1012.
43. Sober AJ, Chuang TY, Duvic M et al. Guidelines of care for primary cutaneous melanoma. J Am Acad Dermatol 2001: 45: 579-586.
44. Kashani-Sabet M. Melanoma genomics. Curr Oncol Rep 2004: 6: 401-405.
45. Myers RP, Benhamou Y, Bochet M, Thibault V, Mehri D, Poynard T. Pegylated interferon alpha 2b and ribavirin in HIV/hepatitis C virus-coinfected nonresponders and relapsers to IFN-based therapy. AIDS 2004: 18: 75-79.
46. Kovacs JA, Vogel S, Metcalf JA et al. Interleukin-2 induced immune effects in human immunodeficiency virus-infected patients receiving intermittent interleukin-2 immunotherapy. Eur J Immunol 2001: 31: 1351-1360.
47. Mitsuyasu R. Immune therapy: nonhighly active antiretroviral therapy management of human immunodeficiency virus-infected patients. J Infect Dis 2002: 185 (Suppl. 2): S115-S122.
48. Goedert JJ, Cote TR, Virgo P et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998: 351: 1833-1839.
49. Maurer TA, Christian KV, Kerschmann RL et al. Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. Arch Dermatol 1997: 133: 577-583.
50. Lobo DV, Chu P, Grekin RC, Berger TG. Nonmelanoma skin cancers and infection with the human immunodeficiency virus. Arch Dermatol 1992: 128: 623-627.
51. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002: 138: 758-763.
52. Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000: 92: 1500-1510.
53. Maurer TA, Christian KV, Kerschmann RL et al. Cutaneous squamous cell carcinoma in human immunodeficiency virus-infected patients. A study of epidemiologic risk factors, human papillomavirus, and p53 expression. Arch Dermatol 1997: 133: 577-583.
54. Harwood CA, McGregor JM, Proby CM, Breuer J. Human papillomavirus and the development of nonmelanoma skin cancer. J Clin Pathol 1999: 52: 249-253.
55. Black AP, Ogg GS. The role of p53 in the immunobiology of cutaneous squamous cell carcinoma. Clin Exp Immunol 2003: 132: 379-384.
56. Mitsuishi T, Kawana S, Kato T, Kawashima M. Human papillomavirus infection in actinic keratosis and Bowen's disease: comparative study with expression of cell-cycle regulatory proteins p21 (Waf1/Cip1), p53, PCNA, Ki-67, and Bcl-2 in positive and negative lesions. Hum Pathol 2003: 34: 886-892.
57. Daling JR, Weiss NS, Hislop TG et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987: 317: 973-977.
58. Berry G, Billingham M, Alderman E et al. The use of cardiac biopsy to demonstrate reduced cardiotoxicity in AIDS Kaposi's sarcoma patients treated with pegylated liposomal doxorubicin. Ann Oncol 1998: 9: 711-716.
59. Durante AJ, Williams AB, Da Costa M, Darragh TM, Khoshnood K, Palefsky JM. Incidence of anal cytological abnormalities in a cohort of human immunodeficiency virus-infected women. Cancer Epidemiol Biomarkers Prev 2003: 12: 638-642.
60. Palefsky JM, Holly EA, Ralston ML et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J AIDS Hum Retrovirol 1998: 17: 320-326.
61. Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis 2002: 35: 1127-1134.
62. Nguyen P, Vin-Christian K, Ming ME, Berger T. Aggressive squamous cell carcinomas in persons infected with the human immunodeficiency virus. Arch Dermatol 2002: 138: 758-763.
63. Koutsky LA, Ault KA, Wheeler CM et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002: 347: 1645-1651.
64. Franceschi S, Arniani S, Balzi D, Geddes M. Survival of classic Kaposi's sarcoma and risk of second cancer. Br J Cancer 1996: 74: 1812-1814.
65. Tam HK, Zhang ZF, Jacobson LP et al. Effect of highly active antiretroviral therapy on survival among HIV-infected men with Kaposi's sarcoma or non-Hodgkin lymphoma. Int J Cancer 2002: 98: 916-922.
66. Tirelli U, Bernardi D. Impact of HAART on the clinical management of AIDS-related cancers. Eur J Cancer 2001: 37: 1320-1324.
67. Jones JL, Hanson DL, Dworkin MS, Jaffe HW. Incidence and trends in Kaposi's sarcoma in the era of effective antiretroviral therapy. J AIDS 2000: 24: 270-274.
68. Chang Y, Cesarman E, Pessin MS et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994: 266: 1865-1869.
69. Boshoff C, Chang Y. Kaposi's sarcoma-associated herpes-virus: a new DNA tumor virus. Annu Rev Med 2001: 52: 453-470.
70. Marchioli CC, Love JL, Abbott LZ et al. Prevalence of human herpesvirus 8 DNA sequences in several patient populations. J Clin Microbiol 1996: 34: 2635-2638.
71. Brambilla L, Boneschi V, Ferrucci S, Taglioni M, Berti E. Human herpesvirus 8 infection among heterosexual partners of patients with classical Kaposi's sarcoma. Br J Dermatol 2000: 143: 1021-1025.
72. Tedeschi R, Caggiari L, Silins I et al. Seropositivity to human herpesvirus 8 in relation to sexual history and risk of sexually transmitted infections among women. Int J Cancer 2000: 87: 232-235.
73. Rabkin CS, Goedert JJ, Biggar RJ, Yellin F, Blattner WA. Kaposi's sarcoma in three HIV-1-infected cohorts. J AIDS 1990: 3 (Suppl. 1): S38-S43.
74. Martin JN, Ganem DE, Osmond DH, Page-Shafer KA, Macrae D, Kedes DH. Sexual transmission and the natural history of human herpesvirus 8 infection. N Engl J Med 1998: 338: 948-954.
75. Casper C, Wald A, Pauk J, Tabet SR, Corey L, Celum CL. Correlates of prevalent and incident Kaposi's sarcoma-associated herpesvirus infection in men who have sex with men. J Infect Dis 2002: 185: 990-993.
76. Rezza G, Andreoni M, Dorrucci M et al. Human herpes-virus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst 1999: 91: 1468-1474.
77. Vitale F, Viviano E, Perna AM et al. Serological and virological evidence of nonsexual transmission of human herpesvirus type 8 (HHV8). Epidemiol Infect 2000: 125: 671-675.
78. Cattani P, Capuano M, Cerimele F et al. Human herpes-virus 8 seroprevalence and evaluation of nonsexual transmission routes by detection of DNA in clinical specimens from human immunodeficiency virus-seronegative patients from central and southern Italy, with and without Kaposi's sarcoma. J Clin Microbiol 1999: 37: 1150-1153.
79. Cattani P, Cerimele F, Porta D et al. Age-specific seroprevalence of human herpesvirus 8 in Mediterranean regions. Clin Microbiol Infect 2003: 9: 274-279.
80. Bourboulia D, Whitby D, Boshoff C et al. Serologic evidence for mother-to-child transmission of Kaposi's sarcoma-associated herpesvirus infection. JAMA 1998: 280: 31-32.
81. Mayama S, Cuevas LE, Sheldon J et al. Prevalence and transmission of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in Ugandan children and adolescents. Int J Cancer 1998: 77: 817-820.
82. Antman K, Chang Y. Kaposi's sarcoma. N Engl J Med 2000: 342: 1027-1038.
83. Serraino D, Toma L, Andreoni M et al. A seroprevalence study of human herpesvirus type 8 (HHV8) in eastern and Central Africa and in the Mediterranean area. Eur J Epidemiol 2001: 17: 871-876.
84. Martin JN, Osmond DH. Determining specific sexual practices associated with human herpesvirus 8 transmission. Am J Epidemiol 2000: 151: 225-229.
85. Gao SJ, Alsina M, Deng JH et al. Antibodies to Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) in patients with multiple myeloma. J Infect Dis 1998: 178: 846-849.
86. Simpson GR, Schulz TF, Whitby D et al. Prevalence of Kaposi's sarcoma-associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet 1996: 348: 1133-1138.
87. Cannon M, Cesarman E. Kaposi's sarcoma-associated herpes virus and acquired immunodeficiency syndrome-related malignancy. Semin Oncol 2000: 27: 409-419.
88. Foster CB, Lehrnbecher T, Samuels S et al. An IL-6 promoter polymorphism is associated with a lifetime risk of development of Kaposi's sarcoma in men infected with human immunodeficiency virus. Blood 2000: 96: 2562-2567.
89. Montella M, Franceschi S, Geddes M, Arniani S, Cocchiarella G. Classic Kaposi's sarcoma and volcanic soil in southern Italy. Lancet 1996: 347: 905.
90. Biggar RJ. AIDS-related cancers in the era of highly active antiretroviral therapy. Oncology (Huntingt) 2001: 15: 439-449.
91. Lebbe C, Blum L, Pellet C et al. Clinical and biological impact of antiretroviral therapy with protease inhibitors on HIV-related Kaposi's sarcoma. AIDS 1998: 12: F45-F49.
92. Chan J, Kravcik S, Angel JB. Development of Kaposi's sarcoma despite sustained suppression of HIV plasma viremia. J AIDS 1999: 22: 209-210.
93. Cattelan A, Calabro M, Gasperini P et al. Acquired immunodeficiency syndrome-related Kaposi's sarcoma regression after highly active antiretroviral therapy: biologic correlates of clinical outcome. J Natl Cancer Inst Monogr 2001: 44-49.
94. Krischer J, Rutschmann O, Hirschel B, Vollenweider-Roten S, Saurat JH, Pechere M. Regression of Kaposi's sarcoma during therapy with HIV-1 protease inhibitors: a prospective pilot study. J Am Acad Dermatol 1998: 38: 594-598.
95. Pellet C, Chevret S, Blum L et al. Virologic and immunologic parameters that predict clinical response of AIDS-associated Kaposi's sarcoma to highly active antiretroviral therapy. J Invest Dermatol 2001: 117: 858-863.
96. European guidelines for the clinical management and treatment of HIV-infected adults in Europe. AIDS 2003: 17 (Suppl. 2): S3-S26.
97. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Ann Intern Med 2002: 137: 381-433.
98. Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK. Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the panel on clinical practices for treatment of HIV. MMWR Recomm Rep 2002: 51: 1-55.
99. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004 recommendations of the International AIDS Society-USA panel. JAMA 2004: 292: 251-265.
100. Brodt HR, Kamps BS, Helm EB, Schofer H, Mitrou P. Kaposi's sarcoma in HIV infection: impact on opportunistic infections and survival. AIDS 1998: 12: 1475-1481.
101. Gill PS, Tulpule A, Espina BM et al. Paclitaxel is safe and effective in the treatment of advanced AIDS-related Kaposi's sarcoma. J Clin Oncol 1999: 17: 1876-1883.
102. Tulpule A, Groopman J, Saville MW et al. Multicenter trial of low-dose paclitaxel in patients with advanced AIDS-related Kaposi's sarcoma. Cancer 2002: 95: 147-154.
103. Nasti G, Errante D, Talamini R et al. Vinorelbine is an effective and safe drug for AIDS-related Kaposi's sarcoma: results of a phase II study. J Clin Oncol 2000: 18: 1550-1557.
104. Torresin A, Cassola G, Penco G, Crisalli MP, Piersantelli N. Vinca alkaloids and macrolides in human immunodeficiency virus-related malignancies: a safe association. Cancer Chemother Pharmacol 1996: 39: 176-177.
105. Hernandez DE, Perez JR. Advanced epidemic Kaposi's sarcoma: treatment with bleomycin or combination of doxorubicin, bleomycin, and vincristine. Int J Dermatol 1996: 35: 831-833.
106. Gill PS, Rarick M, McCutchan JA et al. Systemic treatment of AIDS-related Kaposi's sarcoma: results of a randomized trial. Am J Med 1991: 90: 427-433.
107. Gill P, Rarick M, Bernstein-Singer M et al. Treatment of advanced Kaposi's sarcoma using a combination of bleomycin and vincristine. Am J Clin Oncol 1990: 13: 315-319.
108. Scadden DT, Bering HA, Levine JD et al. GM-CSF as an alternative to dose modification of the combination zidovudine and interferon-alpha in the treatment of AIDS-associated Kaposi's sarcoma. Am J Clin Oncol 1991: 14 (Suppl. 1): S40-S44.
109. Gill PS, Mitsuyasu RT, Montgomery T et al. AIDS clinical trials group study 094: a phase I/II trial of ABV chemotherapy with zidovudine and recombinant human GM-CSF in AIDS-related Kaposi's sarcoma. Cancer J Sci Am 1997: 3: 278-283.
110. Stewart S, Jablonowski H, Goebel FD et al. Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi's sarcoma. International pegylated liposomal doxorubicin study group. J Clin Oncol 1998: 16: 683-691.
111. Gill PS, Wernz J, Scadden DT et al. Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi's sarcoma. J Clin Oncol 1996: 14: 2353-2364.
112. Money-Kyrle JF, Bates F, Ready J, Gazzard BG, Phillips RH, Boag FC. Liposomal daunorubicin in advanced Kaposi's sarcoma: a phase II study. Clin Oncol (R Coll Radiol) 1993: 5: 367-371.
113. Muggia FM. Liposomal encapsulated anthracyclines: new therapeutic horizons. Curr Oncol Rep 2001: 3: 156-162.
114. Nunez M, Saballs P, Valencia ME et al. Response to liposomal doxorubicin and clinical outcome of HIV-1-infected patients with Kaposi's sarcoma receiving highly active antiretroviral therapy. HIV Clin Trials 2001: 2: 429-437.
115. Hengge UR, Brockmeyer NH, Baumann M, Reimann G, Goos M. Liposomal doxorubicin in AIDS-related Kaposi's sarcoma. Lancet 1993: 342: 497.
116. Pfrommer C, Tebbe B, Tidona CA et al. Progressive HHV-8-positive classic Kaposi's sarcoma: rapid response to interferon alpha-2a but persistence of HHV-8 DNA sequences in lesional skin. Br J Dermatol 1998: 139: 516-519.
117. Krown SE. Management of Kaposi's sarcoma: the role of interferon and thalidomide. Curr Opin Oncol 2001: 13: 374-381.
118. Kondlapoodi P. Interferon in the treatment of Kaposi's sarcoma. N Engl J Med 1983: 309: 923-924.
119. Soler RA, Howard M, Brink NS, Gibb D, Tedder RS, Nadal D. Regression of AIDS-related Kaposi's sarcoma during therapy with thalidomide. Clin Infect Dis 1996: 23: 501-503.
120. Little RF, Wyvill KM, Pluda JM et al. Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000: 18: 2593-2602.
121. Saiag P, Pavlovic M, Clerici T et al. Treatment of early AIDS-related Kaposi's sarcoma with oral all-trans-retinoic acid: results of a sequential nonrandomized phase II trial. Kaposi's sarcoma ANRS study group. Agence Nationale de Recherches sur le SIDA. AIDS 1998: 12: 2169-2176.
122. Gill PS, Espina BM, Moudgil T et al. All-trans retinoic acid for the treatment of AIDS-related Kaposi's sarcoma: results of a pilot phase II study. Leukemia 1994: 8 (Suppl. 3): S26-S32.
123. Simonart T, Van Vooren JP, Meuris S. Treatment of Kaposi's sarcoma with human chorionic gonadotropin. Dermatology 2002: 204: 330-333.
124. Hillman JD, Peng AT, Gilliam AC, Remick SC. Treatment of Kaposi's sarcoma with oral administration of shark cartilage in a human herpesvirus 8-seropositive, human immunodeficiency virus-seronegative homosexual man. Arch Dermatol 2001: 137: 1149-1152.
125. Von Roenn JH. Clinical presentations and standard therapy of AIDS-associated Kaposi's sarcoma. Hematol Oncol Clin North Am 2003: 17: 747-762.
126. Geara F, Le Bourgeois JP, Piedbois P, Pavlovitch JM, Mazeron JJ. Radiotherapy in the management of cutaneous epidemic Kaposi's sarcoma. Int J Radiat Oncol Biol Phys 1991: 21: 1517-1522.
127. Cooper JS, Fried PR, Laubenstein LJ. Initial observations of the effect of radiotherapy on epidemic Kaposi's sarcoma. JAMA 1984: 252: 934-935.
128. Margaretic D, Faj D, Tomas I, Dmitrovic B, Krajina Z. Total skin electron treatment of extensive cutaneous lesions in Kaposi's sarcoma. Croat Med J 2002: 43: 342-345.
129. Schweitzer VG. Photodynamic therapy improves Kaposi's sarcoma in AIDS patients. Am Fam Physician 1988: 38: 260.
130. Bernstein ZP, Wilson BD, Oseroff AR et al. Photofrin photodynamic therapy for treatment of AIDS-related cutaneous Kaposi's sarcoma. AIDS 1999: 13: 1697-1704.
131. Tappero JW, Berger TG, Kaplan LD, Volberding PA, Kahn JO. Cryotherapy for cutaneous Kaposi's sarcoma (KS) associated with acquired immune deficiency syndrome (AIDS): a phase II trial. J AIDS 1991: 4: 839-846.
132. Shimomura S, Kikuchi Y, Oka S, Ishitoya J. Local treatment of AIDS-associated bulky Kaposi's sarcoma in the head and neck region. Auris Nasus Larynx 2000: 27: 335-338.
133. Brambilla L, Boneschi V, Beretta G, Finzi AF. Intralesional chemotherapy for Kaposi's sarcoma. Dermatologica 1984: 169: 150-155.
134. Epstein JB, Scully C. Intralesional vinblastine for oral Kaposi's sarcoma in HIV infection. Lancet 1989: 2: 1100-1101.
135. Boudreaux AA, Smith LL, Cosby CD, Bason MM, Tappero JW, Berger TG. Intralesional vinblastine for cutaneous Kaposi's sarcoma associated with acquired immunodeficiency syndrome. A clinical trial to evaluate efficacy and discomfort associated with infection. J Am Acad Dermatol 1993: 28: 61-65.
136. Epstein JB. Treatment of oral Kaposi's sarcoma with intralesional vinblastine. Cancer 1993: 71: 1722-1725.
137. Ghyka G, Alecu M, Halalau F, Coman G. Intralesional human leukocyte interferon treatment alone or associated with IL-2 in non-AIDS related Kaposi's sarcoma. J Dermatol 1992: 19: 35-39.
138. Dupuy J, Price M, Lynch G, Bruce S, Schwartz M. Intralesional interferon-alpha and zidovudine in epidemic Kaposi's sarcoma. J Am Acad Dermatol 1993: 28: 966-972.
139. Gill PS, Lunardi-Ishkandar Y, Louie S et al. The effects of preparations of human chorionic gonadotropin on AIDS-related Kaposi's sarcoma. N Engl J Med 1996: 335: 1261-1269.
140. Walmsley S, Northfelt DW, Melosky B, Conant M, Friedman-Kien AE, Wagner B. Treatment of AIDS-related cutaneous Kaposi's sarcoma with topical alitretinoin (9-cis-retinoic acid) gel. Panretin gel North American study group. J AIDS 1999: 22: 235-246.
141. Cannon MJ, Laney AS, Pellett PE. Human herpesvirus 8: current issues. Clin Infect Dis 2003: 37: 82-87.
142. Martin DF, Kuppermann BD, Wolitz RA, Palestine AG, Li H, Robinson CA. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche ganciclovir study group. N Engl J Med 1999: 340: 1063-1070.
143. Mocroft A, Youle M, Gazzard B, Morcinek J, Halai R, Phillips AN. Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea Westminster Hospitals collaborative group. AIDS 1996: 10: 1101-1105.
144. Glesby MJ, Hoover DR, Weng S et al. Use of antiherpes drugs and the risk of Kaposi's sarcoma: data from the multicenter AIDS cohort study. J Infect Dis 1996: 173: 1477-1480.
145. Spector SA, McKinley GF, Lalezari JP et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche cooperative oral ganciclovir study group. N Engl J Med 1996: 334: 1491-1497.
146. Robles R, Lugo D, Gee L, Jacobson MA. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed Kaposi's sarcoma in patients with AIDS. J AIDS Hum Retrovirol 1999: 20: 34-38.
147. Morfeldt L, Torssander J. Long-term remission of Kaposi's sarcoma following foscarnet treatment in HIV-infected patients. Scand J Infect Dis 1994: 26: 749-752.
148. Krown SE. Therapy of AIDS-associated Kaposi's sarcoma: targeting pathogenetic mechanisms. Hematol Oncol Clin North Am 2003: 17: 763-783.